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Jing Zhao,1 Idowu Akinsanmi,1 Dalia Arafat,1 T.J. Cradick,2 Ciaran M. Lee,2,3 Samridhi Banskota,1
Urko M. Marigorta,1 Gang Bao,2,3 and Greg Gibson1,*
In order to evaluate whether rare regulatory variants in the vicinity of promoters are likely to impact gene expression, we conducted a
novel burden test for enrichment of rare variants at the extremes of expression. After sequencing 2-kb promoter regions of 472 genes in
410 healthy adults, we performed a quadratic regression of rare variant count on bins of peripheral blood transcript abundance from
microarrays, summing over ranks of all genes. After adjusting for common eQTLs and the major axes of gene expression covariance,
a highly significant excess of variants with minor allele frequency less than 0.05 at both high and low extremes across individuals
was observed. Further enrichment was seen in sites annotated as potentially regulatory by RegulomeDB, but a deficit of effects was asso-
ciated with known metabolic disease genes. The main result replicates in an independent sample of 75 individuals with RNA-seq and
whole-genome sequence information. Three of four predicted large-effect sites were validated by CRISPR/Cas9 knockdown in K562 cells,
but simulations indicate that effect sizes need not be unusually large to produce the observed burden. Unusually divergent low-fre-
quency promoter haplotypes were observed at 31 loci, at least 9 of which appear to be derived from Neandertal admixture, but these
were not associated with divergent gene expression in blood. The overall burden test results are consistent with rare and private regu-
latory variants driving high or low transcription at specific loci, potentially contributing to disease.Introduction
In recent years, whole-exome sequencing has been used
effectively to demonstrate that there is a burden of rare
coding variants in individuals with a variety of neurolog-
ical and developmental conditions.1–4 Considering esti-
mates that as many as 90% of disease-associated common
variants are regulatory rather than structural,5–7 it is
reasonable to assume that rare regulatory variants influ-
encing the expression of causal genes might also be en-
riched in individuals with congenital abnormalities or
common chronic diseases. Here we demonstrate that there
is a burden of rare variants with gene expression itself,
focusing on just the promoter regions of a targeted set of
genes whose expression was measured by microarray anal-
ysis of peripheral blood samples.
Our strategy, outlined in Figure 1, gains statistical power
by pooling rare variant enrichments across the full range of
expression of 472 genes measured in 410 individuals. This
effectively generates almost 200,000 data points, but
instead of focusing on just the most extreme individuals
as required by burden tests designed for case-control com-
parisons,8–11 we evaluate the shape of the distribution of
cumulative counts of rare variants in equal sized bins
of expression. For each gene in each individual, 2 kb of
DNA sequence flanking the annotated transcription start
site was sequenced after targeted capture of genomic
DNA on custom beads.12 The count of rare variants
with minor allele frequency less than 5% (or 1%) was as-
sessed after alignment to the HuRef19 reference human
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The Americcounts were summed for 82 equal sized successive gene
expression bins with 5 individuals each, and then tallied
for all 472 genes.
Under the null hypothesis, there should be no relation-
ship between rare variant count and gene expression and a
plot of rare variant count on the y axis against expression
bin on the x axis should yield a horizontal regression line.
In the presence of rare variants that decrease expression,
there should be larger counts in the low expression bins,
toward the left in the plots in Figure 2, and similarly rare
variants that increase expression should yield larger
counts in the higher expression bins to the right. A general
bias toward either effect would result in a significant linear
slope term in a regression model. However, if both effects
are present, a characteristic ‘‘smile’’ plot would ensue, the
significance of which would be reflected in the quadratic
term of a regression. We further assessed departure from
the null by evaluating the significance of the complete
quadratic model relative to 10,000 permutations of the
full genotype and gene expression matrices, subsequently
adjusting for various covariates to gain further insight into
the nature of the burden of rare variants for extreme
expression.
Although deleterious coding variants are generally loss
of function, deleterious regulatory variants have similar a
priori probabilities of increasing or decreasing transcript
abundance. In fact, evolutionary studies14,15 imply that
gene expression is generally subject tomoderate stabilizing
selection, which acts to maintain transcript levels close to
an optimal level. Thus, it is unlikely that many large effect
mutations remain in the gene pool for extended periods ofTechnology, Atlanta, GA 30332, USA; 2Wallace H. Coulter Department of
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Figure 1. Schema Showing the Pooling Strategy to Evaluate Rare Variant Enrichment
For each gene, the normalized gene expressionmeasures across all 410 individuals are sorted into 82 bins, resulting in somewhat normal
frequency distributions shown in the top panels. Subsequently, the number of rare variants in the 2-kb promoter of each allele in that bin
is tallied: for example, there are 2, 1, 0, 0, and 1 rare variants in the promoters of the 5 individuals (both alleles) in the second bin for gene
1, summing to 4, whereas the second bin for gene 2 has 3 rare variants. These expression bin rare allele counts are then summed over all
472 genes and plotted from lowest to highest bin to yield plots at the bottom of the figure that represent two alternative results. In the
absence of a burden of rare variants at the extremes, there is neither a significant slope nor quadratic fit (left plot), whereas an excess of
variants at both extremes produces a concave ‘‘smile’’ regression (right plot). If there were an excess at only the low or high expression,
the linear slope would be significant.time, because purifying selection ensures that only moder-
ate effect alleles persist. One class of haplotype that is
particularly interesting in this regard is the few percent of
alleles that can be traced to introgression from Neandertal
or Denisovan populations.16–18 Although divergent at the
genotype level and occasionally associated with extreme
traits such as high-altitude adaptation,19 the maintenance
of such haplotypes over several tens of thousands of gener-
ations leads to the expectation that they are not likely to300 The American Journal of Human Genetics 98, 299–309, Februarycollectively influence gene expression, a proposition that
we also test here.Material and Methods
Targeted Promoter Sequencing
DNA was obtained from 410 participants in the Atlanta CHDWB
study,20,21 under approval of the Emory University and Georgia4, 2016
Tech IRBs for genetic studies, and including written informed con-
sent. The 410 samples comprised 274 females and 136 males, and
included 297 individuals of European ancestry, 95 of African
ancestry, and 18 of Asian ancestry. The age at entry into the pro-
gram and initial sampling of blood spanned from 19 to 83 with
a mean of 50.
A set of 500 genes was initially chosen for targeted promoter
sequencing, but 28 of these located in the HLA complex were
removed due to irregular read counts in the complex, resulting
in a set of 472 genes that were included in the study. The full list
is included as Table S1, and metrics of sequence quality along
with a list of all promoter variants is available as additional mate-
rial at the author’s website (see Web Resources). Among the 472
genes, 207 have common cis-eQTL, 244 are represented on the
Metabochip, and 220 are represented on the Immunochip, 145
of which are on both chips.
Whole-genomic DNA was isolated from buffy coats using Flexi-
gene DNA kits (QIAGEN). The location of the major transcription
start site (TSS) of each gene was extracted from the UCSC Genome
Browser (accessedMay 2012), and oligonucleotide probes were de-
signed with the Illumina Design Studio so as to pull down 1 kb up-
stream and 1 kb downstream of the major TSS for each of the
472 genes. 50-mer oligonucleotide probes were designed to ensure
that the percentage of the total length of all regions targeted for
enrichment was not less than 90%. Sequence capture libraries
were generated and pooled with Illumina TruSeq DNA Sample
Preparation Kits and TruSeq Custom Enrichment Kits. Paired end
100 bp sequencing was then performed on an Illumina HiSeq
2500 at Georgia Tech. Approximately 75% of the aligned reads
with BWA mapped to the 2-kb promoter regions of the 472 genes,
indicating good enrichment to the targeted regions. The average
read depth across the dataset was more than 6003, with more
than 90% of the reads in the 2-kb promoter regions having more
than 203 read depth.Variant Calling
After short read alignment, a variety of different strategies for
variant calling were evaluated and contrasted, leading to the deci-
sion to use the output of the GATKUnified Genotyper algorithm13
applied to all samples in a pooled analysis. First, the BWA aligner
was used to align fastq files to HuRef19. The total number of
aligned reads per sample ranged from approximately 2 million
to 40 million, with a mean of 14 million and standard deviation
of 5 million. The mapped reads proportion was between 94.1%
and 99.9% with a mean of 99.3% and a standard deviation of
1.05%. The percentage of concordantly paired reads ranged from
92.9% to 98.9% with a mean of 97.9% and a standard deviation
of 1.2%. The GATK VQSR tool was used for variant filtering using
the Illumina Omni chip array based on the 1000 Genomes Project
as the training data with the highest-confidence SNPs from the
1000 Genomes Project’s call set used to validate the SNPs, utilizing
a machine learning approach to optimize cutoffs for QD (quality
by depth ratio), FS (Fisher’s exact test of strand bias), MQ (mapping
quality metric), HaplotypeScore, MQRankSum (Mann-Whitney
rank sum test for mapping qualities), and ReadPosRankSum
(Mann-Whitney rank sum test for the distance of reads with the
alternate allele to the end of the read).
After variant calling, we detected 17,584 raw SNPs in total, but
these were reduced to 10,451 SNPs passing the filters, that lie
within the 2-kb promoter regions of 472 genes. 8,833 of the
SNPs are rare (defined as MAF < 0.05 in our dataset, which isThe Americconcordant with 1000 Genomes frequencies) and 1,618 are com-
mon (with MAFR 0.05), which averages 1.5 rare variants per pro-
moter per individual. Approximately 60% of these rare variants are
private, meaning that they were observed in only a single individ-
ual. The number of rare, common, and private SNPs per gene,
along with an estimate of the polymorphism rate (p) per gene in
the 2-kb sequenced region, as well as a matrix of rare allele counts
per gene in each individual are available at the author’s website.Verification by Sanger Sequencing and Genotyping
To verify the accuracy of the high-throughput sequencing, we
Sanger sequenced 500 bp segments of two genes, TRAF3IP3
(OMIM: 608255) and HSPA8 (OMIM: 600816). The sequenced re-
gion of TRAF3IP3 was chr1: 209,929,132–209,929,708, in which
two rare SNPs and four common SNPs were observed in the 410
samples. All of these were included in 96 samples that were Sanger
sequenced, and all were validated. The sequenced region of HSPA8
was chr11: 122,932,665–122,933,158, which contained 18 rare
and 5 common SNPs in the 96 sequenced samples, which were
again verified by Sanger sequencing. A handful of other individ-
uals were nominally positive at some of the rare sites, but manual
inspection of the traces revealed poor-quality sequence toward the
ends of the reads in those individuals suggesting a false positive
rate that in any case would be less than 0.5%. No other variants
that were not present in the GATK analysis were called with
high confidence by Sanger sequencing, whereas all common vari-
ants were also validated by the Sanger sequencing.
Whole-genome genotypes either from Illumina OmniExpress or
CoreþExome arrays, imputed onto 1000 Genomes with
Impute2,22 were also available for the majority of individuals.
Extremely high concordance was observed. These genotypes
were thus used for common variant eQTL analysis, which will be
described in detail elsewhere. We also interrogated whether rare
SNPs lie within the Illumina probes, but found just three examples
in two genes, so these do not explain enrichment of rare variants
downstream of the promoter with gene expression.Gene Expression Profiling
Transcript abundance measures were generated in two batches us-
ing Illumina-HT12 human gene expression arrays. RNA was pre-
pared from whole-blood samples collected and stored in Tempus
tubes (Life Technologies), according to manufacturer-recommen-
ded protocols, and quality was confirmed with an Agilent Bio-
analyzer such that all samples had RIN numbers greater than 8.
The first batch of samples was processed for hybridization and
bead intensity extraction by Expression Analysis and the second
by HudsonAlpha. The raw data are available at the Gene Expres-
sion Omnibus (GEO) but additional data processing steps were
employed for this study to account for batch effects that might
have skewed the rare variant association statistics.
Raw expression data in the form of average bead intensities from
the Illumina Genome Studio were first transformed to log2 values
and then processed with two standard approaches for removing
surrogate variables. For PEER analysis23 of the Europeans only
(Figure S1A), batch effects were removed with ComBat,24 and
then age and gender were fit in a general linear model, before
fitting the PEER algorithm with 20 factors selected, 6 of which
were notably stronger than the remainder. As an additional
mode of analysis, surrogate variable analysis (SVA),25 we con-
sidered the full dataset, after removing batch effects with
COMBAT, then used SVAwith age as the biological variable, fittingan Journal of Human Genetics 98, 299–309, February 4, 2016 301
a single surrogate variable identified by the open source R code.
Because ethnicity still explained 9% of the variance and age and
gender each approximately 0.5%, we removed these as linear
terms, then extracted just the 279 European-ancestry samples for
rare variant enrichment tests as described below, generating very
similar results as with PEER. However, for most analyses reported
below, we used normalization based on supervised normalization
of microarrays (SNM) algorithm in R,26 without fitting the surro-
gate variables. We fit age as the biological variable and removed
effects of batch and ethnicity by including these as adjustment
variables with the rm ¼ True option. Individual effects were ac-
counted for as the intensity-dependent variable.
We next extracted the 472 genes for which we have promoter
genotypes and averaged the estimates for 172 genes that are repre-
sented by two (132 genes) or more (40 genes) probes in the Illu-
mina-HT12 arrays. Each gene expression distribution was then
transformed to the same scale, namely to z-scores, which are stan-
dard normal distributions with amean of 0 and standard deviation
of 1. To ensure that there was no overall batch effect on the vari-
ances (namely, that individuals from one batch are not, for tech-
nical reasons, more likely to have extreme values), we fit the
z-scores by batch and combined them into a single gene expres-
sion dataset that was used to generate all of the results reported
here. Quantile normalization27 was also performed in parallel
(Figure S1B) because it is commonly used in the literature. Quan-
tile normalization ensures that the distribution of abundance esti-
mates of the entire gene expression profile of each individual is the
same but does not ensure adjustment of covariates influencing
the variance (or average expression) of each gene. It was applied
to the raw log2 distributions of each individual, and probes for
the same gene were again averaged prior to assigning genes to
expression bins for the regression on rare variant counts.Rare Variant Burden Test
In order to evaluate whether there was a relationship between
transcript abundance and number of rare variants in the promoter,
for each gene, each individual was placed in one of 82 equal-sized
bins of five individuals based on the rank of the batch-adjusted z-
scores.We then tallied the number of rare variants in the promoter
regions of those five individuals and subsequently summed the
rare variant counts across all 472 genes to achieve statistical power
to detect the overall burden. With a MAF cutoff of 0.05, only 1 ho-
mozygote is expected per gene, but because most rare variants are
rarer than this, the actual number of homozygotes is too small to
impact the sums, but they were counted twice in the tally at the
gene level. The bin size was chosen as a compromise between
smooth fitting of the quadratic regression and compensating for
noise in individual gene expression measures assessed by microar-
ray. However, additional analyses were performed with 41 bins of
size 10 individuals (Figure S1E) or with MAF < 0.01 (Figure S1F),
neither of which had a meaningful effect on the conclusions
because both remain highly significant for enrichment at both ex-
tremes. We then evaluated the deviation of the distribution from
the null hypothesis of no relationship by fitting a quadratic model
where the linear term captures bias toward enrichment for either
higher or lower expression and the quadratic term captures the ef-
fect of bias at both extremes simultaneously.
The significance values of the two terms were observed to be
very similar to the empirical p values obtained by permuting the
sum counts against the bin number. We also performed a more
robust permutation to shuffle the genotype and gene expression302 The American Journal of Human Genetics 98, 299–309, Februaryvectors, keeping the full vector of promoter counts within each in-
dividual (and the full vector of expression ranks) constant so as to
preserve any biological covariance. With the appropriately
normalized gene expression data, such permutations generally re-
sulted in flat regressions of allele count on expression bin, with
non-significant linear and quadratic terms. We then evaluated
the significance of the actual data by documenting howmany per-
mutations out of 10,000 have a more significant overall model fit,
which is just a few cases, strengthening support for the inference
(1) that the normalization has removed systematic biases and (2)
that there is a true burden of rare variants at either extreme of
the transcript distribution, averaging across 472 transcripts.
A further adjustment was made to account for unequal total
read counts among individuals or in specific genes as follows.
For the analyses involving mixed races, we performed a haplotype
burden analysis by collapsing all multi-SNP promoters down to a
count of 1, instead of the actual number of rare variants. This
should be conservative because it will tend to underestimate the
contributions of two or more variants in a single promoter. We
also fit a ‘‘joint’’ analysis (Figure S1C) where instead of binning
gene expression solely within individuals, we generated 82 bins
of 2,100 gene expression measures (5 3 420), based in the ranked
z-scores of all genes in all individuals, and performed the regres-
sion on the summed allele counts associated with the 2,100
measures. In this procedure, each gene contributes slightly dispro-
portionately to each bin, yet the overall result was again retained.Adjustment of Rare Variant Burden Test for Covariates
A variety of biological factors could mask the effect of rare variants
by increasing the variance of gene expression. Two obvious effects
are the contribution of common eQTLs, which will tend to cause
individuals with the less active polymorphism to be in lower
expression bins, and trans-acting sources of gene expression
covariance. Because peripheral blood preserved in Tempus tubes
is a complex mixture of leukocytes (residual red blood cell and
platelet gene expression is thought not to contribute strongly to
observed transcript abundance), an obvious source of covariance
is cell counts. Cell counts (lymphocytes, monocytes, neutrophils,
erythrocytes, and platelets) explain on average just 6.0% of the
variance of each transcript abundance measure in our dataset,
which is actually one quarter of the amount explained by seven
empirically determined common axes of covariance (average
23.8%: compare Figures S2A and S2B for distributions of variance
explained). These axes probably reflect a mixture of the contribu-
tions of cell counts and coordinate gene regulation for example by
interferon or other systemic factors. The seven axes are defined by
the first principal component of the expression of ten ‘‘blood
informative transcripts (BITs)’’ per axis, where the BITs have
been defined by comparison of multiple blood gene expression da-
tasets.28 Note that fitting PC1 to the 5 or 100 most correlated tran-
scripts in each axis results in almost identical axis scores.
Simple linear regression was used to fit both eQTL and co-
expression axes. For the eQTL adjustment, we first performed
whole-genome cis-eQTL analysis on the full CHDWB dataset and
identified significant eQTLs located within 5 kb of the TSS or in
the gene body for 207 of the 472 genes at p < 104, observing
more than 70% overlap with the blood eQTL browser variants
derived from meta-analysis of more than 5,000 samples.29 For
approximately one fifth of the genes, multiple additional cis-
eQTLs were observed conditioned on the primary eQTL. We
used stepwise linear regression to fit these empirical eQTLs in4, 2016
our dataset, also including age and sex as covariates in the model
(although neither age nor sex account for more than a few percent
of the variance of any of the 472 genes). The residuals from the
eQTL fit were then used for axis adjustment, for which we
computed the seven PC1 scores from the full SNM normalized
gene expression matrix, and then identified which axis was most
strongly correlated with the expression of each gene (8,654 were
influenced by an axis at p < 105, including 398 of the 472 genes
included in the enrichment analyses). Univariate linear regression
was then used to fit the relevant axis for each gene, yielding gene
expression residuals that were taken forward to the adjusted
burden test.Partitioning the Sources of Rare Variant Burden on
Gene Expression
Several potential modifiers of the rare variant contribution were
evaluated by dividing the total European ancestry dataset into sub-
sets and comparing the model fit. For example, to evaluate
whether suspected regulatory sites are more likely to harbor rare
variants, we downloaded the RegulomeDB30 assignments for
each SNP and contrasted sites with scores in the ranges 1–4 (likely
regulatory) or 5–7 (weak or no evidence for regulatory potential).
Similar analyses reported in Table S1 contrast SNPs upstream
and downstream of the TSS; SNPs in genes in the upper or lower
halves of the overall average transcript abundance spectrum;
SNPs in genes in the upper or lower halves of the average promoter
polymorphism distribution; SNPs in genes with or without com-
mon eQTLs; and SNPs in genes represented on the Metabo-
chip,31 Immunochip,32 or neither. For each comparison, we report
the significance of the quadratic term and the linear term as well as
the overall model fit alongside the average number of rare variants
per gene in the two samples being compared.Assessment of Archaic Origins of Haplotypes
Because 289 of the promoter sequences in the European ancestry
samples (0.2%) have three or more substitutions relative to the
reference human genome, we asked whether they might be
derived from archaic genomes. For each of the 472 genes, vcftools
v.3.033 was used to query the online sequences of the Neandertal
individual from an Altai Mountain cave34 and the Denisovan indi-
vidual from the same cave.35 62 of the genes were not covered in
the sequence. For the remaining 410 genes, we identified 195
positions where one of the 7,779 polymorphisms in our European
individual promoter sequence set matched either of the archaic ge-
nomes rather than HuRef19. 75 genes had haplotypes with 3 or
more sites different from HuRef19; of these, 18 had haplotypes
matching a Neandertal haplotype. 31 genes had haplotypes with
4 or more sites different from HuRef19; of these, 8 had haplotypes
matching a Neandertal haplotype. In several cases, a Denisovan
haplotype was similar to the Neandertal one, but the Neandertal
matched the human sequences, so as expected all archaic alleles
identified in our dataset are most likely of Neandertal origin.
Table S2 shows the genotypes of the 22 individuals with archaic
haplotypes in the 8 genes with 4 or more divergent sites.
The expected proportion of Neandertal alleles genome-wide is
between 1% and 2%, which is an order of magnitude greater
than the proportion observed in our data. A very conservative
lower bound on the proportion of divergent Neandertal promoters
is 67 of 289 haplotypes, or 0.06% of all promoters. Including pro-
moters with just 2 non-reference sites, approximately 10% of
which match a Neandertal allele, this proportion rises to 0.1%.The AmericSingle divergent sites at least double this proportion again. But
owing to the possibility of recurrent mutation and recombination,
we chose not to include such sites in analysis of association of
Neandertal alleles with gene expression, because they need to be
assessed by reference to long-range archaic haplotype blocks. It
should also be noted that the Altai individual represents only a
fraction of all archaic polymorphisms. Our observed proportion
of Neandertal-derived alleles in the divergent promoters, at least
20%, can be considered to be within the expected range given
that some alleles are also related to rare haplotypes observed in
the African-ancestry individuals and might have been retained
from the out-of-Africa dispersal.Replication Dataset
In order to replicate the rare variant enrichment on a completely
independent dataset generated with different gene expression
and genotyping technologies, we identified a small cohort of 75
individuals with whole-genome sequence and whole-blood RNA-
seq at the Duke Center for Human Genome Variation (D.B. Gold-
stein, P.I.). Most of these individuals are from a schizophrenia
study. Permission to perform genetic analysis was obtained under
IRB approval of Duke University, affirmed by the Georgia Tech IRB,
and written informed consent was obtained from all study sub-
jects, their parent/guardian, or legally authorized representative.
Analysis of the principal components of the genotypes indicated
that the sample includes 49 individuals of African ancestry, 24
of European ancestry, and 2 of Asian ancestry.
Whole-genome sequences were obtained on Illumina Hi-
Seq2000 automated DNA sequencers and genotypes were called
individually with the GATK algorithm. RNA-seq of whole blood
preserved in Tempus tubes was performed also by paired end
100 bp sequencing on the Illumina platform. Raw read counts
were log2 transformed and mean centered, and linear regression
fitting each of the seven axes of variation (represented by PC1 of
the blood informative transcripts) as well as the overall PC1 of
gene expression variation (which is correlated with genetically
determined ancestry). Subsequently, we assigned the rank of
each gene in each individual and performed quadratic regression
of the total number of individuals with at least one rare allele
count for the gene (MAF< 0.05) in each of 75 ranks. That is, rather
than pooling five individuals per bin, the analysis was essentially
on bin sizes of 1, necessitated by the small sample of individuals.Experimental Validation of SNP Effects by Genome
Editing
Four SNPs were chosen for experimental validation by CRISPR/
Cas9-mediated genome editing.36 Two (chr6: 24,667,167 in
TDP2 [OMIM: 605764] and chr20: 33,999,719 in UQCC1
[OMIM: 611797]) were associated with loss of gene expression
and two (chr5: 54,603,837 in DHX29 [OMIM: 612720] and
rs182080358 in COMMD4 [HGNC: 26027]) with gain of gene
expression in the CHDWB targeted sequencing analysis
(Table S3). These four sites were all present as private alleles in
one individual and were in the outlier set for an effect size greater
than 2 SDs, visible in Figure 2A. For each SNP, we generated 11 or
12 independent approximately 10-cell K562 clones targeted by
guide RNAs. Although K562 cells are erythroleukemic, rather
than lymphoid or myeloid, because the variants are promoter
proximal, we reasoned that they might have effects generally on
transcript abundance and this cell line is well established for
CRISPR experiments. Each promoter region in the cell line wasan Journal of Human Genetics 98, 299–309, February 4, 2016 303
Figure 2. Relationship between Rare Variant Counts and Tran-
script Abundance
Each plot shows the cumulative number of rare variants in equal
sized bins across the indicated number of genes and individuals,
with lowest expression bin to the left and highest to the right.
Lines indicate the best fit quadratic model.
(A) 472 genes in 410 individuals of mixed ethnicity (5 individuals
per bin), gene expression data normalized by SNM with variance
adjustment (whole model R2 ¼ 0.19, p ¼ 0.0003).
(B) 472 genes in 279 Europeans (93 bins of 3 individuals) after
removing effects of common eQTLs and conserved axes of covari-
ation (R2 ¼ 0.17, p ¼ 0.0003).
(C) 4,633 genes in 75 replicates after removing effects of conserved
axes of covariation and PC1 (R2 ¼ 0.49, p ¼ 2 3 1011).
304 The American Journal of Human Genetics 98, 299–309, Februaryre-sequenced to confirm that it is homozygous for the reference
allele, also as reported for the publically available K562 sequence.
DNA oligonucleotides containing a G followed by 19-nt guide
sequence were kinased, annealed, and ligated into pX330 (gift
from Feng Zhang, Addgene plasmid #42230). The four guide
RNAs were COMMD4, 50-GCGCCAAGAAGCCAGGGCCC-30;
DHX29, 50-GCTCTCACTGCTCCCAAAAA-30; TDP2, 50-GTGCGCA
GGCGCCTGTGTCA-30; and UQCC, 50-GGTGAAGGAGTAATTTT
CTA-30. Once constructed, the plasmids were sequenced to
confirm the guide strand region using the primer CRISPR_Seq
(50-CGATACAAGGCTGTTAGAGAGATAATTGG-30). K562 cells
(1 3 106) were transfected by nucleofection with 1 mg CRISPR
plasmid construct for COMMD4, DHX29, TDP2, or UQCC and
300 ng of pmaxGFP, according to manufacturer’s recommended
protocol (Lonza). GFP expression was analyzed 72 hr after trans-
fection at which time DNA and RNA were prepared from pooled
cells for preliminary analysis.
After a period of 4 to 10 days of growth, transfected cells were
sorted by fluorescence activated cell sorting (FACS) and GFP-posi-
tive single cells or 10-cell colonies were sorted into 96-well plates.
These were allowed to incubate for 2–4 weeks or until confluent
and then subjected to T7E1 mutation detection assay37 in which
the region of interest was amplified and 200 ng of purified PCR
product was re-annealed and digested with T7 endonuclease 1.
Cleavage was confirmed by the appearance of reduced molecular
weight bands on 2% agarose gels that were quantified by ImageJ
in order to estimate the fractional heterozygosity.
After confirming disruption of each relevant SNP by the T7E1
assay, five clones were chosen for each of the four genes with
average heterozygosity between 16% and 23%. Droplet PCR,38
which is capable of detecting a 20% modulation of gene expres-
sion, was used with HPRT (OMIM: 308000) as a uniform control
gene in all analyses, with UQCC as a second control for TDP2
and DHX29, and with TDP2 as the second control for UQCC and
COMMD4 disrupted clones. In each experiment we contrasted
the relative expression of the knocked out gene in the five clones
to its average expression in five clones carrying a knockout of
another gene (that is, TDP2 for DHX29 and vice versa; UQCC for
COMMD4 and vice versa), performing a t test of the comparison.
Differential expression was computed by formulating the ratio
of each ddPCR count for the gene of interest to each reference
gene, normalizing these ratios such that the average in the control
cells was 1, then averaging the ratios to the two references. The
average and significance of the change in expression is reported
in Table S3 and Figure S3, which shows the proportional reduction
or gain in signal for the five clones of each type, measured in two
technical replicates of each clone.Results
Figure 2A illustrates the core result that there is enrichment
of rare variants for both increased and decreased gene
expression in the full sample (model R2 ¼ 0.19, p ¼
0.0003, permutation p ¼ 0.0002). This is true for a variety
of modes of normalization of the gene expression data
detailed in the Material and Methods section, including a
conservative strategy involving removal of batch effects
with Combat24 followed by fitting age and gender followed
by fitting PEER factors23 to just the European-ancestry in-
dividuals (Figure S1A), simple quantile normalization274, 2016
(Figure S1B), surrogate variable analysis,25 and an
approach that first pooled the z-scores for all of the gene
expression measures before assigning bins (Figure S1C).
In subsequent analyses we employed supervised normali-
zation of microarrays (SNM)26 because it optimally con-
trols for confounding between technical and biological
sources of variance. The full dataset consisted of 297 indi-
viduals of European ancestry, 18 of East Asian ancestry, and
95 of predominantly African ancestry, but because African
ancestry is associated with mild differential expression of
one third of the genes and an almost 4-fold elevation in
rare variant counts in the promoter regions (consistent
with HapMap estimates39,40), we also considered each of
the two larger population groups separately. The same
trend was observed in both the European and African
American samples but with only marginal significance in
the latter due to the reduced sample size. Similarly, the
result holds when we replaced total rare variant counts
with rare haplotype counts, noting that some individuals
carry alleles that differ from the reference allele at two or
more sites. Because some genes show flatter distributions
of expression in African ancestry samples, there is an
excess of African ancestry at the extremes for the com-
bined analysis, which we conservatively corrected by addi-
tionally standardizing the gene expression within each
population group, which reduced the strength of the asso-
ciation with rare variant counts, particularly for increased
expression (Figure S1D). Larger sample sizes will be
required to explore whether there are population differ-
ences in rare variant contributions.
Further evidence that the regression models truly cap-
ture enrichment for rare variants at extremes of gene
expression comes from the observation that the fit and sig-
nificance improve after adjustment for covariates that are
known to influence gene expression. Figure 2B shows the
model fit for the Europeans (so as to avoid false positives
due to population stratification) when gene expression
bins were reassigned to the residuals after also fitting
known common variant eQTL effects29 for each gene, as
well as principal component scores for seven common
axes of peripheral blood gene expression covariance.28
These seven axes collectively explain an average of 26%
of the expression variance of the 472 genes (range 2% to
89%), which is approximately four times as much as the
variance explained by the major cell types in whole blood
(average 6%, range 0% to 44%; Figure S5). Fitting common
eQTLs and the axis scores improves themodel R2 from 0.05
(p ¼ 0.07) to 0.17 (p ¼ 0.0003, permutation p < 0.0001).
Next we asked whether the enrichment might be attrib-
uted to particular classes of gene or gene region, summari-
zing the results in Table S1 and Figure S4. First, categorizing
all variants with respect to predicted regulatory potential
according to RegulomeDB30 classifications confirms that
variants that lie within features such as DNase hypersensi-
tive sites or transcription factor binding sites (classes 1–4)
are more enriched at the extremes than all other variants
in classes 5–7 (p ¼ 0.002 versus 0.08). Second, surprisingly,The Americthe enrichment was much stronger for variants located
downstream of the transcription start site (p ¼ 0.0007)
versus upstream (p¼ 0.09). Third, we investigated whether
there was a difference between overall low-abundance and
high-abundance transcripts by dividing the dataset into
two halves according to that parameter, but no difference
was noted. Analyzing the genes separately in sets with
low, intermediate, and high levels of promoter polymor-
phism suggests that the enrichment is observed across all
levels of polymorphism. Notably as well, the burden re-
mains when we reduced the minor allele frequency
threshold to 0.01 (Figure S1F), reflecting the fact that the
majority of rare variants are found in five or fewer
individuals.
The most striking differential enrichment was observed
with respect to gene function. The 472 genes were chosen
for analysis in order to obtain approximately equal repre-
sentation with respect to two criteria: whether or not
they contain known common variant eQTLs, and whether
or not they are thought to be associated with common
chronic diseases. Genes not represented on the Metabo-
Chip31 are significantly more likely to be enriched for
rare regulatory variants (p ¼ 93 106 versus 0.73 for meta-
bolic disease-related genes). To confirm that this is signifi-
cant, we compared the deviation in R-squared values with
those of 1,000 random partitions of the European dataset
keeping the number of individuals in the two sets con-
stant, and observed that the Metabochip deviation is to-
ward the tail (p ¼ 0.007). A similar trend was observed
for genes on the Immunochip,32 p ¼ 0.005 versus 0.11,
but this difference was not significant relative to the
random partitions. These trends toward reduced rare regu-
latory SNP presence in promoters of disease-associated
genes might be explained by relaxation of purifying selec-
tion on genes not associated with disease.
The possibility that some genes are more tolerant of regu-
latory variants is also implied by the observation that genes
with common eSNPs are much more likely to harbor
rare promoter-proximal variants affecting gene expression
(p ¼ 0.0006) than those without (p ¼ 0.11). Furthermore,
genes with low promoter polymorphism (p50P) relative to
coding region polymorphism (pcod) highlighted in
Figure 3A are highly significantly depleted for rare variants
in the top decile of effect sizes inferred from our data
(Figure 3B; t test contrasting number in bottom 10% of
low p50P / pcod genes against the remainder, p ¼ 3 3 105).
The deficit is not due solely to low polymorphism because
the contrast remains significant when p50P is included as a
covariate, and the bottom 10% of p50P genes overall are as
likely to harbor large effect rare variants as all other genes.
This result raises the possibility thatmore extensive analyses
of rare regulatory variant association with transcript abun-
dance in different tissuesmight give rise to ameasure of pro-
moter region tolerance to functionalmutation similar to the
RVIS41 and constraint scores42 that classify genes with
respect to intolerance to disruptive and pathogenic protein
mutations.an Journal of Human Genetics 98, 299–309, February 4, 2016 305
Figure 3. Genes with a Low Ratio of Pro-
moter to Coding Polymorphism Are Intol-
erant to Large Effect Regulatory Variants
(A) Regression of p50P on pcod highlighting
the bottom 10% of genes with the largest
negative residuals (lowest ratio, red) and
top 10% (blue).
(B) Plot of relationship between the num-
ber of variants per gene in the top decile
of estimated effect size from all 8,833 rare
variants (MAF < 0.05) and residual from
the regression in (A) as a measure of rela-
tive promoter polymorphism.Another potential source of functional regulatory varia-
tion is divergent promoters derived from admixture with
archaic humans. We identified 31 genes in the dataset
that harbor haplotypes with 4 or more rare variants in Eu-
ropeans, and for 8 of these genes (26%), the divergent
haplotype matches informative Neandertal or Denisovan
sequences. Similarly, 15 of 75 (20%) haplotypes with 3 or
more rare variants appear to be archaic, whereas less diver-
gent haplotypes are more likely to be generated by succes-
sivemutations in the human lineage. The remaining diver-
gent haplotypes might represent Neandertal alleles not
found in the Altai cave individual, as-yet-unrecognized
archaic lineages, or fast-evolving alleles also present in
the African gene pool. Two of the non-archaic divergent
haplotypes, both also found in multiple African ancestry
individuals in our sample, were likely to associate with
elevated expression, in CDK10 (2 individuals, two-tailed
t test p ¼ 1.210) and NDUFB10 (12 individuals, two-tailed
t test p ¼ 0.0028). By contrast, there was no tendency for
any of the archaic haplotypes to be associated with
extreme expression in peripheral blood. Further analyses
imputing ancestry based on long-range haplotypes from
multiple Neandertal individuals, and assessments in multi-
ple tissues, might nevertheless define roles for archaic pro-
moter polymorphism in gene regulation.
In order to estimate the frequency and magnitude of ef-
fects that would be consistent with the observed enrich-
ments, we performed a simulation study where effects
were assigned to the empirically determined genotypes
and added to randomly generated and normally distributed
gene expression values. Figure 4A shows the actual observed
effects from the data, and this distribution is compared
with those drawn from a gamma(1.5, 0.12) distribution
(Figure4B) that generates results comparable to theobserved
enrichment (Figure4C). Theestimatedeffect sizesunder this
model are somewhat smaller than those estimated from the
data, probably a consequenceof samplingoverestimation in
the experiment and the absence of technical noise in the
simulated data. However, the result suggests that observed
effect sizes are very rarely greater than 2 SDs and that most
of the enrichment is driven by rare variants with influences
comparable to those of common eQTLs, namely allelic sub-
stitutions in the range of 0.5 to 1 SD.
Next we replicated the result with an independent data-
set consisting of 75 whole-genome sequences of mixed306 The American Journal of Human Genetics 98, 299–309, Februaryancestry, linked to whole-blood RNA-seq profiles.
Figure S5 shows that the same trend was observed with
the 472 genes as in the Atlanta cohort, but owing to the
small sample size of individuals the result is only signifi-
cant at p ¼ 0.008. However, increasing the analysis to
include the same total number of comparisons as in the
CHDWB, namely 4,633 genes, and adjusting for the axes
of variation as well as a strong surrogate variable corre-
sponding to ancestry provides clear replication of the
rare variant enrichment (R2 ¼ 0.49, p ¼ 2 3 1011, permu-
tation p < 0.0001; Figure 2C).
To experimentally validate rare variant regulatory effects
predicted from the statistical analysis, we used CRISPR/
Cas9 to mutagenize four sites that had estimated effect
sizes greater than 5-fold higher or lower than the popula-
tion mean in a single individual, in K562 erythroleukemia
cells.43 11 individual clones were grown for each disrup-
tion and once cleavage was confirmed via the T7E1
assay,37 indicating 16% to 23% average heterozygosity,
5 clones were chosen for RNA abundance measurement.
Droplet digital RT-PCR,38 which quantifies relative abun-
dance by counting the number of nanodroplets from a
dilution of the RNA sample that yield PCR product, as-
sessed relative to control genes, was used to demonstrate
that disruption of three of the four sites resulted in reduced
or increased transcript abundance (Table S3). Disruption of
rs182080358 associated with increased expression of
COMMD4 weakly increased transcript abundance in three
of the four clones and greatly increased it in another. All
five clones with disruptions in UQCC reduced expression
almost by half, whereas disruption of a negative control site
had no effect and four of five clones with disruptions in
TDP2 reduced expression to varying degrees (Figure S3).
Because our CRISPR protocol causes small deletions rather
than targeted replacement of polymorphisms, it is ex-
pected that the disruptions remove binding sites for tran-
scriptional activators in each case. This could cause loss
or gain of expression depending on the nature of the tran-
scription factor, but it is notable that in each case the effect
of disruption was in the same direction as the nucleotide
substitution. The difference in estimated effect size might
be attributed to over-estimation of the effect from the mi-
croarray data and underestimation in the CRISPR clones
that have incomplete heterozygosity because K562 cells
are largely triploid.434, 2016
Figure 4. Estimation of Effect Sizes of Rare Variants
(A) The distribution of absolute values of the estimated effect size
from the CHDWB data as a function of the number of alleles in the
sample. Boxes showmean and interquartile range with whiskers at
1.5 times IQR with outliers as single points.
(B) Comparison of estimated effect size distribution from the data
(bold curve) and in the simulation (thin black curve) showing
slight excess of larger effect variants in the observed data.
(C) Simulated model fit assuming a gamma distribution with
gamma(1.5,0.12), for 472 genes in 279 individuals, showing
excess of extreme expression as in the actual data (R2 ¼ 0.18,
p ¼ 0.0002).Discussion
These experiments demonstrate that the combination of
gene sequencing with transcript profiling in peripheral
blood has good potential as a screening approach to iden-The Americtify rare promoter-proximal variants that significantly
disrupt the regulation of gene expression. Although the
average effect sizes we estimate are not large, they are on
a par with those estimated for disease-associated common
eQTLs.29 That is to say, large-effect rare variants typically
alter expression of a gene between one half and one stan-
dard deviation unit. For a transcript otherwise expressed
in the inter-quartile range, namely in the middle half of
the distribution, this will often be enough to cause it to
shift it to the upper or lower decile where it would presum-
ably be more likely to contribute to pathology or
abnormality.
Two other studies have also found indirect evidence for
rare variant influences on gene expression in cell lines,
albeit spread across extended cis-regulatory regions. Mont-
gomery et al.44 performed eQTL analysis on the 1000
Genomes Project lymphoblast cell lines and observed
that transcripts with rare instances of allele-specific expres-
sion (ASE) had a median of four perfectly concordant rare
putative regulatory variants within 100 kb of the TSS,
compared with three for control transcripts not exhibiting
ASE. Interestingly, the enrichment was greater for non-syn-
onymous than synonymous coding ASE variants and
biased to lower expression, suggesting an epistatic interac-
tion between regulatory and structural polymorphism.
They also found that very rare alleles in conserved putative
regulatory sites were more likely to be 2 SDs from the
mean. Reanalyzing the Geuvadis lymphoblast cell line
data, Zeng et al.45 focused on rare instances where the cor-
relation between two transcripts was aberrant in a few in-
dividuals and described an enrichment of private variants
specifically in the vicinity of enhancers in the 1 Mb region
of the genes.
We do not observe any tendency for variants to be more
likely to increase or decrease gene expression, which is
consistent with the inference that globally, transcript
abundance is under stabilizing selection.14,15 Recent re-
sults from yeast46 also indicate that there is selection
against noise promoted by regulatory variants, so it will
be interesting in larger studies to evaluate whether genes
with reduced promoter relative to coding polymorphism
also tend to have reduced expression variability due to
rare variants.
If our experimental strategy can be applied to tissues or
cell types directly relevant to certain pathologies, such as
neurons or cardiac cells, it could enhance efforts to infer
whether rare variants in regulatory regions are functionally
deleterious. It is possible that iPSC culture might be bene-
ficial in this regard, particularly if the effects on transcrip-
tion are greater in uniform cell culture than in mixed
whole-blood cell populations from individuals who
experience a wide range of environments. By extrapolation
from our data, we estimate that the average individual
probably carries several dozen such variants that cause
gene expression to be toward the extreme, and conse-
quently these cannot be ignored as a potential source of
disease-related pathology. Determination of whether oran Journal of Human Genetics 98, 299–309, February 4, 2016 307
not rare regulatory variants are sufficient to cause rare dis-
eases in the samemanner as structural variants are inferred
to will require experimental designs targeted to individuals
with particular congenital disorders.Accession Numbers
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